Spring Bank Pharmaceuticals (SBPH) PT Cut At Cantor After Inarigivir Lauch Delay
Tweet Send to a Friend
Cantor Fitzgerald analyst, Elemer Piros, reiterated his Overweight rating on shares of Spring Bank Pharmaceuticals (NASDAQ: SBPH) but cut his ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


